Valneva's Stock Rebounds 2.34% After a 12% Drop Over the Week
Valneva's stock shows a rebound of 2.34% this Wednesday, reaching 4.46 euros, after a challenging week marked by a decline of over 12%. The vaccine specialist's stock is trading close to its 20-day moving average, as the market awaits the publication of its annual 2025 results scheduled for March 16.
Valneva Regains Ground
Valneva's stock is recovering this Wednesday after losing more than 12% over the past seven sessions. This correction comes despite the stock previously showing a quarterly increase of over 20% and an annual rise of 32%. Technically, the stock is oscillating around its 20-day moving average (4.47 euros), which currently acts as a short-term pivot. The 50-day moving average, at 4.19 euros, continues to support the medium-term upward trend. The RSI, at 57, indicates a neutral condition, without excessive buying or selling, leaving the stock in a balanced zone after recent profit-taking.
Key Catalyst Identified for Coming Weeks
The main catalyst identified for the upcoming weeks is the publication of the annual 2025 results, scheduled for March 16. This event will be crucial in assessing the financial trajectory of the Nantes-based laboratory, particularly the evolution of its revenue from the commercialization of vaccines against chikungunya and Japanese encephalitis. The financial calendar then schedules the first-quarter results for May 7, followed by the general meeting on June 1. It should be noted that the monthly volatility of the stock remains high, at 16.53%, while its beta of 0.44 indicates a moderate sensitivity to general market fluctuations. The stock is currently trading in the middle range of the channel bounded by its support at 3.89 euros and its resistance at 5.08 euros.
